For example, angiotensin-converting enzyme inhibitors,23 beta-adrenergic blockers,24 mineralocorticoid receptor antagonists,25 sacubitril/valsartan,26 and most recently SGLT2 inhibitors27 have been shown to reduce arrhythmogenic sudden cardiac death—and, in the case of SGLT2 inhibitors, the incidence of AF,28 which was not the case for the other upstream therapies. Here, SLC5A2 is linked to atrial fibrillation.